Human Psychopharmacology: Clinical and Experimental
Open accessThe DOI matches its Crossref record.
Abstract
Objective: To examine whether concomitant amlodipine use was associated with steady-state serum olanzapine concentration and clinical outcomes in patients with schizophrenia.Methods: This retrospective study included 45 inpatients with schizophrenia and hypertension who received olanzapine 10 mg/ day plus amlodipine 5 mg/day (experimental group) and 52 inpatients who received olanzapine 10 mg/day alone (control group).PANSS and SDSS scores were assessed at baseline and week 7, and recorded adverse events were evaluated at week 9. Results: Mean serum olanzapine concentration was lower in the combination group than in the olanzapine-alone group (40.56 ± 18.86 vs. 50.23 ± 23.41 ng/mL; unadjusted p = 0.027; age-adjusted p = 0.032) (Figure 1).Improvements in positive symptoms, negative symptoms, and SDSS scores were smaller in the combination group, whereas PANSS total and general psychopathology changes did not differ.Serum olanzapine concentration was not significantly correlated with any PANSS or SDSS change.Recorded adverse-event rates did not differ significantly.Conclusions: Concomitant amlodipine use was associated with lower serum olanzapine concentration and smaller improvements in selected clinical domains.The individual-level analyses did not establish a concentration-response relationship, and the retrospective design precludes causal inference.Haemodynamic safety could not be evaluated because complete standardised blood-pressure data were unavailable.These findings suggest that closer monitoring of clinical response and serum olanzapine concentrations may be considered when amlodipine is co-prescribed, particularly in patients with suboptimal treatment response. | IntroductionSchizophrenia is a chronic mental disorder associated with substantial personal, family, and societal burden (Velligan and Rao 2023).People with schizophrenia also experience marked excess cardiovascular morbidity and premature mortality, driven by an interaction among illness-related factors, smoking, cardiometabolic risk, antipsychotic exposure, and inequalities in physical health care (Correll et al. 2017;Murphy and Daumit 2023;Polcwiartek et al. 2024).Hypertension is therefore a common and clinically important comorbidity in this population (Sudarshan and Cheung 2023).Olanzapine remains widely used because of its efficacy across several symptom domains,
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Metal–organic frameworks as photoluminescent biosensing platforms: mechanisms and applications
Zhao, Y., Zeng, H., Zhu, X.-W., Lu, W., & Li, D. (2021) · Chemical Society Reviews · doi:10.1039/d0cs00955e · Cited by 690
Masuda, T., Misawa, F., Takase, M., Kane, J. M., & Correll, C. U. (2019) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2019.1702 · Cited by 319
Hong, L. E., Gu, H., Yang, Y., Ross, T. J., Salmeron, B. J., Buchholz, B., Thaker, G. K., & Stein, E. A. (2009) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.2 · Cited by 260
Aetiology and treatment of nightmare disorder: State of the art and future perspectives
Gieselmann, A., Ait Aoudia, M., Carr, M., Germain, A., Gorzka, R., Holzinger, B., Kleim, B., Krakow, B., Kunze, A. E., Lancee, J., et al. (2019) · Journal of Sleep Research · doi:10.1111/jsr.12820 · Cited by 195
Fusar-Poli, P., Allen, P., Bhattacharyya, S., Crippa, J. A., Mechelli, A., Borgwardt, S., Martin-Santos, R., Seal, M. L., O'Carrol, C., Atakan, Z., et al. (2010) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145709990617 · Cited by 163
Metadata
- Venue
- Human Psychopharmacology Clinical and Experimental
- Publisher
- Wiley
- Published
- 2006-03-07
- ISSN
- 0885-6222 (ISSN-L)
- 1099-1077
- OpenAlex
- W4249097380
- Cited by
- 122
- References
- 0
- Type
- paratext
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Human Psychopharmacology: Clinical and Experimental. https://app.cochat.ai/papers/10.1002/(issn)1099-1077
- The paper
- Human Psychopharmacology: Clinical and Experimental. (2006). Human Psychopharmacology Clinical and Experimental. https://doi.org/10.1002/(issn)1099-1077
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.